Search Result

Pathways Recommended:	Metabolic Enzyme/Protease

Results for "

metabolic dysfunction-associated steatohepatitis mice

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (1) AMPK (1) Amylases (1) Angiotensin-converting Enzyme (ACE) (1) ATP Citrate Lyase (1) Dipeptidyl Peptidase (1) Drug Derivative (1) FABP (2) FXR (5) G protein-coupled Bile Acid Receptor 1 (2) GABA Receptor (2) GLUT (1) Glycosidase (1) Heme Oxygenase (HO) (1) Keap1-Nrf2 (1) Lipase (1) NF-κB (1) NOD-like Receptor (NLR) (1) P2Y Receptor (1) p38 MAPK (1) PPAR (4) Pyroptosis (1) Quinone Reductase (1) Reactive Oxygen Species (ROS) (1) SARS-CoV (1) Thyroid Hormone Receptor (1) TNF Receptor (2)
By Research Areas:	Cancer (1) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (8) Metabolic Disease (9)

By Targets:

ACSL Family (1)

AMPK (1)

Amylases (1)

Angiotensin-converting Enzyme (ACE) (1)

ATP Citrate Lyase (1)

Dipeptidyl Peptidase (1)

Drug Derivative (1)

FABP (2)

FXR (5)

G protein-coupled Bile Acid Receptor 1 (2)

GABA Receptor (2)

GLUT (1)

Glycosidase (1)

Heme Oxygenase (HO) (1)

Keap1-Nrf2 (1)

Lipase (1)

NF-κB (1)

NOD-like Receptor (NLR) (1)

P2Y Receptor (1)

p38 MAPK (1)

PPAR (4)

Pyroptosis (1)

Quinone Reductase (1)

Reactive Oxygen Species (ROS) (1)

SARS-CoV (1)

Thyroid Hormone Receptor (1)

TNF Receptor (2)

By Research Areas:

Cancer (1)

Cardiovascular Disease (1)

Infection (1)

Inflammation/Immunology (8)

Metabolic Disease (9)

Inhibitors & Agonists

Peptides

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N8599

Cichoriin 2 Publications Verification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB	Infection Metabolic Disease Inflammation/Immunology
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

HY-177704

ACSL5-IN-1	ACSL Family Drug Derivative	Metabolic Disease Cancer
ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer .

HY-P11208C

mNLS-CPP-WSTF TFA	GABA Receptor	Inflammation/Immunology
mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .

HY-178015

THR-β agonist 11	Thyroid Hormone Receptor	Metabolic Disease Inflammation/Immunology
THR-β agonist 11 is an orally active and selective thyroid hormone receptor (THR-β) agonist. THR-β agonist 11 shows potent cholesterol-lowering activity in cholesterol-fed rats. THR-β agonist 11 significantly reduces serum total TG, LDL-cholesterol, liver total TC and TG levels, and alleviates hepatic steatosis, inflammation and fibrosis in HFD-CCl4-induced Metabolic dysfunction-associated steatohepatitis (MASH) model mice. THR-β agonist 11 can be used for the study of metabolic dysfunction-associated steatohepatitis (MASH) and other fibrotic diseases .

HY-P11208

mNLS-CPP-WSTF	GABA Receptor	Inflammation/Immunology
mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .

HY-168629

FXR agonist 9	FXR	Metabolic Disease
FXR agonist 9 (compound 26) is an oral active and selectivity FXR partial agonist with the EC₅₀ of 0.09 µM (75.13 % maximum efficacy). FXR agonist 9 ameliorates pathological features in HFD and CCl₄(HY-Y0298)-induced metabolic dysfunction-associated steatohepatitis mice .

HY-168713

LZ-007	FXR	Metabolic Disease
LZ-007 is an agonist for farnesoid X receptor (FXR) with an EC₅₀ of 51 nM measuring by TR-FRET assay, or an EC₅₀ of 76 nM in HepG2 cell. LZ-007 exhibits good pharmacokinetic characheristics in SD rats. LZ-007 ameliorates western diet and CCl4 (HY-Y0298)-induced mice metabolic dysfunction-associated steatohepatitis

HY-172883

ABP/PPAR modulator 1	FABP PPAR	Metabolic Disease Inflammation/Immunology
ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-172883A

(E/Z)-ABP/PPAR modulator 1	FABP PPAR	Metabolic Disease Inflammation/Immunology
(E/Z)-ABP/PPAR modulator 1 is a mixture of the E and Z isomers of ABP/PPAR modulator 1 (HY-172883). ABP/PPAR modulator 1 is an orally active FABP and PPAR multiple modulator (IC₅₀s of 0.65  μM and 1.08  μM for FABP1 and FABP4, EC₅₀s of 9.19  μM, 2.20  μM and 1.58 μM for PPARα, PPARγ and PPARδ). ABP/PPAR modulator 1 has potent anti-metabolic dysfunction-associated steatohepatitis (MASH) activity. ABP/PPAR modulator 1 dose-dependently ameliorates multiple pathological characteristics of fatty liver in WD + Carbon tetrachloride-induced MASH mice model .

HY-183692

FXR agonist 18	FXR G protein-coupled Bile Acid Receptor 1 TNF Receptor Heme Oxygenase (HO) Quinone Reductase Keap1-Nrf2	Cardiovascular Disease Inflammation/Immunology
FXR agonist 18 is an orally active FXR agonist, with an EC₅₀ of 10 nM against human FXR and an EC₅₀ of 1360 nM against human TGR5. FXR agonist 18 inhibits inflammatory responses by reducing nitrite production, downregulating the expression of pro-inflammatory genes (Tnf, Adgre1, Cyp8b1, upregulating the expression of FXR, Hmox1, Nqo1, Nrf2, and enhancing antioxidant responses. FXR agonist 18 ameliorates liver fibrosis in mice, exhibits protective effects in mice with cholestatic liver injury, and shows anti-MASH efficacy. FXR agonist 18 can be used in studies of metabolic dysfunction-associated steatohepatitis .

HY-179591

BGT-002 326E	ATP Citrate Lyase PPAR	Metabolic Disease
BGT-002 (326E) is an orally active dual ACLY inhibitor and PPARα agonist. BGT-002 reduces lipogenesis by inhibiting synthesis and promoting efflux. BGT-002 demonstrates efficacy in ameliorating metabolic dysfunction-associated steatohepatitis (MASH) and improving hyperlipidemia in vivo. BGT-002 can be used for hypercholesterolemia and MASH research .

HY-182026

FXR agonist 17	FXR G protein-coupled Bile Acid Receptor 1 TNF Receptor Reactive Oxygen Species (ROS)	Inflammation/Immunology
FXR agonist 17 is an orally active, steroidal FXR agonist with EC₅₀ values of 42.2 nM (TR-FRET) and 176.4 nM (luciferase reporter assay), respectively. FXR agonist 17 activates TGR5 (EC₅₀ = 2.6 μM) but does not activate hMRGPRX4. FXR agonist 17 exerts anti-inflammatory, hepatoprotective and antifibrotic effects, improves the non-alcoholic steatohepatitis (NAFLD) activity score and reduces the severity of liver fibrosis. FXR agonist 17 can be used for the research of NAFLD, cholestatic liver disease and liver fibrosis .

HY-183279

FXR antagonist 4	FXR AMPK	Metabolic Disease
FXR antagonist 4 (Compound 4l) is an orally active, selective FXR antagonist with an IC₅₀ of 0.70 μM. FXR antagonist 4 binds to FXR, differentially regulates bile acid and lipid transporter genes, and exerts no effect on gluconeogenesis-related genes. FXR modulator 1 activates the AMPK signaling pathway to inhibit fatty acid synthesis. FXR modulator 1 alleviates hepatic steatosis, ballooning degeneration and fibrosis, and improves dyslipidemia. FXR modulator 1 can be used for research on metabolic dysfunction-associated steatohepatitis .

Cat. No.	Product Name	Target	Research Area

HY-P11208C

mNLS-CPP-WSTF TFA	GABA Receptor	Inflammation/Immunology
mNLS-CPP-WSTF TFA is the trifluoroacetate salt of mNLS-CPP-WSTF (HY-P11208). mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .

HY-P11208

mNLS-CPP-WSTF	GABA Receptor	Inflammation/Immunology
mNLS-CPP-WSTF is a nuclear localization signal (NLS)-cell-penetrating peptide based on the mouse WSTF sequence. mNLS-CPP-WSTF significantly inhibits the GABARAP-WSTF interaction, WSTF degradation and inflammatory gene expression. mNLS-CPP-WSTF effectively attenuates chronic inflammation, liver fibrosis and cartilage damage in metabolic-dysfunction-associated steatohepatitis (MASH) and osteoarthritis (OA) mice model. mNLS-CPP-WSTF is promising for research of chronic inflammatory diseases such as MASH and OA .

Cichoriin 2 Publications Verification	Infection Structural Classification Monophenols other families Classification of Application Fields Coumarins Phenols Phenylpropanoids Plants Disease Research Fields Source Classification	Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB
Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC₅₀ values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y₁₄R (IC₅₀ = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks